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1. INTRODUCTION {#ajco13276-sec-0050}
===============

Following breast‐conserving surgery for breast cancer, a positive surgical margin is widely recognized to increase the risk of local recurrence by at least twofold compared with a negative margin.[1](#ajco13276-bib-0001){ref-type="ref"}, [2](#ajco13276-bib-0002){ref-type="ref"}, [3](#ajco13276-bib-0003){ref-type="ref"} For patients with positive margins after breast‐conserving surgery, the National Comprehensive Cancer Network guidelines and other guidelines recommend re‐excision to ensure that the margins are indeed negative.[4](#ajco13276-bib-0004){ref-type="ref"}, [5](#ajco13276-bib-0005){ref-type="ref"}, [6](#ajco13276-bib-0006){ref-type="ref"} One report has indicated that re‐excision resulted in the detection of residual tumors in 24% to 84% of patients according to the extent of positive margins after breast‐conserving surgery.[7](#ajco13276-bib-0007){ref-type="ref"} The above‐mentioned guidelines recommend that re‐excision should also be performed to secure negative margins in patients with positive margins after mastectomy.[6](#ajco13276-bib-0006){ref-type="ref"} Re‐excision after mastectomy, however, is invasive and frequently difficult to perform because it requires the excision of muscle and ribs in addition to the mammary tissue already removed. Re‐excision of the skin may occasionally be performed if a positive margin is detected after nipple‐sparing mastectomy (NSM). Furthermore, re‐excision increases the risk of complications such as postoperative infection and may delay the initiation of subsequent adjuvant chemotherapy.[8](#ajco13276-bib-0008){ref-type="ref"}, [9](#ajco13276-bib-0009){ref-type="ref"} Thus, for patients with positive or "close" margins after breast‐conserving surgery, boost irradiation to the primary tumor bed is often added to whole‐breast radiation therapy (WBRT). Some reports indicate that additional irradiation can decrease the local recurrence rate in patients with positive/close margins to a rate as low as that in patients with negative margins, whereas other reports indicate that the recurrence rate, even after additional irradiation, remains higher than that in patients with negative margins.[10](#ajco13276-bib-0010){ref-type="ref"}, [11](#ajco13276-bib-0011){ref-type="ref"}, [12](#ajco13276-bib-0012){ref-type="ref"} Moreover, in patients with positive/close margins after mastectomy, including those with axillary lymph node metastasis, postmastectomy RT (PMRT) of the chest wall or regional lymph nodes has widely been recognized to reduce the local recurrence rate and has become standard treatment.[13](#ajco13276-bib-0013){ref-type="ref"}, [14](#ajco13276-bib-0014){ref-type="ref"} Because the number of patients with positive/close margins without axillary lymph node metastasis after mastectomy is small, however, the significance of PMRT in this patient population is unknown. No recommendations have been offered, even in the American Society of Clinical Oncology guidelines.[15](#ajco13276-bib-0015){ref-type="ref"} In the electron intraoperative therapy (ELIOT) study, NSM was combined with intraoperative RT with electrons as a strategy for partial chest wall RT (PCWRT), although patients with positive margins were excluded from the study population.[16](#ajco13276-bib-0016){ref-type="ref"} We performed PCWRT in patients with positive/close margins and no pathological evidence of axillary lymph node metastasis and compared the outcomes with those of patients who did not undergo re‐excision or PCWRT.

2. PATIENTS AND METHODS {#ajco13276-sec-0060}
=======================

Among patients who underwent modified radical mastectomy plus either axillary dissection or sentinel node biopsy for breast cancer between January 2009 and December 2017, 40 patients with positive/close margins who were pathologically shown to have no axillary lymph node metastasis were included in this retrospective study. Postoperatively, 22 patients underwent RT, and 18 did not. None of the 40 patients underwent re‐excision. This study was approved by the Institutional Review Board of Nihon University School of Medicine. Informed consent was obtained from all patients.

2.1. Surgical margin status {#ajco13276-sec-0070}
---------------------------

As is the case after breast‐conserving surgery, a *positive margin* was defined as an invasive carcinoma or a ductal carcinoma in situ (DCIS) microscopically identified ink on tumor tissue (defined as abnormal tissue just touching the ink).[6](#ajco13276-bib-0006){ref-type="ref"} A *close margin* was defined as having a tumor ≤1 mm from the inked resection edge. This definition relied on a shorter distance than that previously accepted (≤10 mm or ≤2 mm).[17](#ajco13276-bib-0017){ref-type="ref"}, [18](#ajco13276-bib-0018){ref-type="ref"}

2.2. Nuclear grading {#ajco13276-sec-0080}
--------------------

Severity was classified according to a three‐point scale (grades 1‐3) based on a composite picture of nuclear atypia and mitotic counts on hematoxylin and eosin‐stained carcinomatous tissue specimens.

2.3. Immunohistological subtypes {#ajco13276-sec-0090}
--------------------------------

Estrogen receptors (ERs) and human epidermal growth factor receptor 2 (HER2) were evaluated by immunohistochemistry (IHC) analysis. HER2 was judged positive when the IHC score was 3+ or there was a positive fluorescence in situ hybridization test result. The Ki‐67 antibody MIB‐1 clone (Dako, Glostrup, Denmark) was used to detect Ki‐67 expression. The Ki‐67 proliferation index was defined as the percentage of cells with positive nuclear Ki‐67 immunostaining in a section of confirmed carcinomatous tissue.

2.4. PCWRT parameters {#ajco13276-sec-0100}
---------------------

The primary tumor bed was contoured by reference to preoperative computed tomography or magnetic resonance imaging, or to a pathological specimen. The clinical target volume (CTV) was defined as the primary tumor bed plus a margin of at least 2 cm with clipping patient and muscle surface and fat. For example, three‐dimensional (3D) conformal RT (CRT) consisting of two tangential beams was planned for the CTV. The field size was set as the partial chest wall measuring ≥9.5 cm in the cephalocaudal dimension (Figure [1](#ajco13276-fig-0001){ref-type="fig"}). Using the thickness of the chest wall as the basis, irradiation of 4‐ to 10‐MV photons or 5‐ to 8‐MeV electrons with or without a bolus to the skin was planned, and 95% of the prescribed isodose volume was used to irradiate the CTV to the maximum extent.

![Representative digitally reconstructed radiograph for partial chest wall radiation therapy. The primary tumor bed (red) and clinical target volume (light red) were contoured. The cephalocaudal length was 12 cm, and did not include the entire chest wall \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](AJCO-16-28-g001){#ajco13276-fig-0001}

2.5. Statistical methods {#ajco13276-sec-0110}
------------------------

SPSS version 21.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Clinicopathological characteristics were compared between groups with and without PCWRT using Pearson\'s *χ* ^2^ test.

3. RESULTS {#ajco13276-sec-0120}
==========

Table [1](#ajco13276-tbl-0001){ref-type="table"} summarizes the patient characteristics with detailed surgical margin status. The median age of patients at mastectomy was 58.5 years in the PCWRT group and 69 years in the no‐RT group. Premenopausal patients accounted for 40.9% of patients in the PCWRT group and 29.4% in the no‐RT group, with the difference not reaching significance. The prevalence of positive margins was 77.3% in the PCWRT group and 27.8% in the no‐RT group, with the difference being statistically significant (*P* = 0.002, Pearson\'s *χ* ^2^ test). In the PCWRT group, significantly more tumors at the margins were DCIS. The most common area of positivity on the positive/close margins was the anterior margin in the PCWRT group and the posterior margin in the no‐RT group. In the no‐RT group, there were significantly more tumors at the posterior margins. Four patients in the PCWRT group and one in the no‐RT group had multiple positive/close areas at the margins. There were no significant differences between the two groups regarding other clinicopathological characteristics. The median total dose of PCWRT was 60 Gy (range 50‐66 Gy). We tended to select a dose ≥60 Gy in the case of invasive carcinoma at the positive margin (in 4 out of 5 patients). Acute RT‐related toxicity was observed in only one patient who had undergone surgical removal of a seroma and manifested as an abscess caused by a bacterial infection after postoperative RT. The abscess resolved following drainage and antibiotic therapy. Other RT‐related toxicities included grade 1 dermatitis and grade 1‐2 pneumonitis (National Cancer Institute Common Terminology Criteria for Adverse Events 4.03).[19](#ajco13276-bib-0019){ref-type="ref"} In both groups, the majority of patients (91.0% and 88.9%, respectively) underwent hormonal therapy, with only a few given chemotherapy. The median follow‐up after mastectomy was 38 months (range 6‐116 months) in the PCWRT group and 48 months (range 23‐60 months) in the no‐RT group. In both groups, the local recurrence‐free survival (RFS) and disease‐free survival (DFS) values were 100%. None of the patients developed a local recurrence.

###### 

Patient characteristics with positive/close margins after mastectomy with pathological *N*0 status

                                      PCWRT                       
  ----------------------------------- -------------- ------------ -----------------------------------------------------
  Characteristics                     N = 22 (%)     N = 18 (%)   
  Age at mastectomy (years)                                       
  Median (range)                      58.5 (38‐75)   69 (33‐84)   0.062[\*](#ajco13276-tbl1-note-0002){ref-type="fn"}
  Premenopausal                       9 (40.9)       5 (27.8)     0.386
  Histology                                                       
  DCIS                                5 (22.7)       2 (11.1)     0.336
  Invasive ductal                     10 (45.5)      12 (66.7)    
  Invasive lobular                    2 (9.0)        3 (16.7)     
  Invasive micropapillary             1 (4.6)        0            
  Mucinous                            3 (13.6)       1 (5.5)      
  Apocrine                            1 (4.6)        0            
  Pathological size (UICC)                                        
  Tis                                 5 (22.7)       2 (11.1)     0.336
  T1                                  9 (40.9)       10 (55.6)    
  T2                                  6 (27.2)       6 (33.3)     
  T3                                  1 (4.6)        0            
  T4                                  1 (4.6)        0            
  Surgical margin                                                 
  Positive                            17 (77.3)      5 (27.8)     **0.002**
  Close (\>0 ≤1 mm)                   5 (22.7)       13 (72.2)    
  Tumor at positive/close margin                                  
  Noninvasive                         15 (68.2)      6 (33.3)     **0.028**
  Invasive                            7 (31.8)       12 (66.7)    
  Tumor at positive margin only                                   
  Noninvasive                         12 (54.5)      3 (16.7)     0.655
  Invasive                            5 (22.7)       2 (11.1)     
  Location of positive/close margin                               
  Anterior                            7 (31.8)       4 (22.2)     0.499
  Superior                            0              0            
  Medial                              4 (18.2)       0            0.057
  Lateral                             6 (27.2)       1 (5.5)      0.072
  Inferior                            3 (13.6)       1 (5.5)      0.397
  Posterior                           7 (31.8)       13 (72.2)    **0.011**
  Nuclear grade                                                   
  1/2                                 21 (95.4)      17 (94.5)    0.884
  3                                   1 (4.6)        1 (5.5)      
  Immunohistological subtypes                                     
  ER+/HER2−                           18 (82.0)      11 (61.2)    0.145
  ER+/HER2+                           2 (9.0)        2 (11.1)     
  ER−/HER2+                           0              2 (11.1)     
  ER−/HER2−                           2 (9.0)        1 (5.5)      
  ER+/HER2 borderline                 0              2 (11.1)     
  Ki‐67 labeling index                                            
   \<10%                              5 (22.7)       6 (33.3)     0.152
   ≥10%                               13 (59.1)      12 (66.7)    
  Unknown                             4 (18.2)       0            
  Hormone therapy                                                 
  Yes                                 20 (91.0)      16 (88.9)    0.832
  No                                  2 (9.0)        2 (11.1)     
  Chemotherapy                                                    
  Yes                                 2 (9.0)        2 (11.1)     0.832
  No                                  20 (91.0)      16 (88.9)    
  Trastuzumab treatment                                           
  Yes                                 2 (9.0)        5 (27.8)     0.122
  No                                  20 (91.0)      13 (72.2)    

Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor 2; PCWRT, partial chest wall radiation therapy; RT, radiation therapy; UICC, Union for International Cancer Control.

Clinicopathological *P* value was calculated using Pearson\'s *χ* ^2^ test for categorical covariates. \**P* value was calculated using Mann‐Whitney U test. Bold type indicates statistical significance.
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4. DISCUSSION {#ajco13276-sec-0130}
=============

Some patients with breast cancer who undergo a mastectomy are node‐negative, and understandably, there may be a reluctance to recommend RT of the entire chest wall. Previous studies have shown that patient characteristics can vary in terms of margin status, presence of axillary lymph node metastasis, and use of PMRT (Table [2](#ajco13276-tbl-0002){ref-type="table"}). The association between margin status and local recurrence after mastectomy without PMRT was investigated in two studies conducted during the 1980s. Both studies addressed the association between the posterior margin (the distance from the tumor margin to the pectoral fascia) and local recurrence.[20](#ajco13276-bib-0020){ref-type="ref"}, [21](#ajco13276-bib-0021){ref-type="ref"} One of the studies included patients with axillary lymph node metastasis,[20](#ajco13276-bib-0020){ref-type="ref"} and the other focused on patients without axillary lymph node metastasis.[21](#ajco13276-bib-0021){ref-type="ref"} Neither study showed any correlation between the distance from the tumor to the posterior margin and local recurrence. In a study that included patients with axillary lymph node metastasis who did not undergo PMRT, the presence of positive/close margins (\<5 mm) after postoperative chemotherapy was associated with an increased risk of locoregional recurrence.[22](#ajco13276-bib-0022){ref-type="ref"} In another study in patients at pathological stage T1‐2 without axillary lymph node metastasis and who did not undergo PMRT, the local recurrence rate was extremely low (1.68%). The study protocol, however, excluded patients with positive margins from the analysis.[23](#ajco13276-bib-0023){ref-type="ref"} In a study involving patients at pathological stage T3 without axillary lymph node metastasis who did not undergo PMRT, the locoregional recurrence rate was 7.1%. Cancer recurred on the chest wall in 85.7% of the patients with recurrence, but the surgical margins were not examined.[24](#ajco13276-bib-0024){ref-type="ref"} In a study conducted in patients aged ≤50 years with positive/close margins (≤6 mm) who did not undergo PMRT, including those with axillary lymph node metastasis, the local recurrence rate was high (23%), indicating that younger patients with positive/close margins might benefit more from PMRT than older patients.[17](#ajco13276-bib-0017){ref-type="ref"} In studies conducted in high‐risk patients, such as those with tumors ≥5 cm who underwent PMRT and those with invasion of the skin or fascia, the locoregional recurrence rate decreased from 17%‐23% to 3%‐6% after PMRT was performed along with chemotherapy or hormone therapy, even in patients without axillary lymph node metastasis. However, the surgical margins were not examined in these studies.[25](#ajco13276-bib-0025){ref-type="ref"}, [26](#ajco13276-bib-0026){ref-type="ref"} In a study involving patients at pathological stage T3 without axillary lymph node metastasis after PMRT and who were selected from the U.S. National Cancer Data Base, PMRT was shown to improve outcomes, regardless of whether the margins were positive or negative.[27](#ajco13276-bib-0027){ref-type="ref"} In that study, the RT field was also analyzed, and regional lymph node area irradiation in combination with chest wall RT was not associated with the outcomes. In a study conducted in patients with positive/close margins (≤2 mm), including those with axillary lymph node metastasis after PMRT, the presence of positive/close margins did not correlate with locoregional recurrence when a 15 or 20 Gy boost dose was delivered to the tumor bed in addition to PMRT.[18](#ajco13276-bib-0018){ref-type="ref"} Regarding the site of local recurrence, some reports have shown that the cancer recurred in the surgical field in 33% to 67% of patients after breast‐conserving surgery.[28](#ajco13276-bib-0028){ref-type="ref"}, [29](#ajco13276-bib-0029){ref-type="ref"} For partial breast irradiation, which has recently been implemented based on these reports, the CTV is defined as an area covering the tumor bed cavity and at least 1 cm of surrounding mammary gland.[30](#ajco13276-bib-0030){ref-type="ref"} In patients who have undergone mastectomy, however, the CTV for RT is difficult to establish because the surrounding mammary gland has been removed. Local chest wall recurrence after mastectomy has reportedly been detected within 7 cm of the inferior margin of the operation\'s transverse scar in ≥97% of patients.[31](#ajco13276-bib-0031){ref-type="ref"} In our patients, who did not have risk factors (eg, axillary lymph node metastasis) other than positive/close margins, the RT field was not expanded to cover the entire chest wall in a uniform manner. Instead, we selected PCWRT with a field having at least 2‐cm margins to the primary tumor bed and measuring ≥9.5 cm in the cephalocaudal dimension. In all previous studies of PMRT, the RT field was all of the chest wall with or without the regional lymph node area. To the best of our knowledge, the current study is the first to report the selection of only part of the chest wall for PMRT. Regarding the sites of positivity on the margin, one study showed that the proportion of patients with residual tumor did not correlate with the presence of four positive mammary gland margin directions (medial, lateral, superior, and inferior) or the presence of two nonmammary gland margin directions (anterior and posterior) in patients undergoing breast‐conserving surgery.[32](#ajco13276-bib-0032){ref-type="ref"} Another study showed that positive nonmammary gland margins are associated with a significantly lower local recurrence rate than positive peripheral mammary gland margins, suggesting that subcutaneous and retromammary fat should be retained during breast‐conserving surgery.[33](#ajco13276-bib-0033){ref-type="ref"} In the present study, the absence of local recurrence might have been attributable to the fact that all patients had undergone mastectomy and had positive/close nonbreast parenchymal margins. RT doses, which have been investigated in patients with positive/close margins (≤2 mm), showed no correlation between the margin status and locoregional recurrence when a 15‐ or 20‐Gy boost dose was delivered to the tumor bed in addition to PMRT at 50 Gy.[18](#ajco13276-bib-0018){ref-type="ref"} Another study showed that when patients with positive margins after breast‐conserving surgery received a 10‐ or 26‐Gy boost dose in addition to WBRT at 50 Gy, there was no difference in the local recurrence rate in the two groups.[34](#ajco13276-bib-0034){ref-type="ref"} After evaluating the results of these studies, we irradiated only part of the chest wall with a total dose of 50‐66 Gy in the present study and achieved good local control. However, local control was also satisfactory in patients without irradiation, and therefore the significance of PCWRT remains unclear. In the present study, the baseline characteristics varied between the two groups. For example, the PCWRT group included significantly more patients with positive margins. When the breast parenchyma was removed by mastectomy, locoregional control might have been more strongly affected by the presence or absence of lymph node metastasis than by the surgical margin status. Limitations of the present study include the relatively short follow‐up period. However, during our review of previous studies on patients' undergoing mastectomy for breast cancer, one study investigated any recurrence that developed within 2 years after the procedure,[26](#ajco13276-bib-0026){ref-type="ref"} and another showed that locoregional recurrence was detected in 88% of patients within 3 years.[27](#ajco13276-bib-0027){ref-type="ref"} Thus, the median follow‐up period in the present study may be considered acceptable. In the present study, both the PCWRT group and the no‐RT group showed equally good local control without re‐excision. We therefore suggest that PCWRT be considered for patients with node‐negative breast cancer after mastectomy if they have positive or close margins, although further studies are required to verify these results.

###### 

Summary of previous studies with/without PMRT after mastectomy for positive/close margins

  Author                                                       Year   Years of patient accrual   No. of positive/close margin patients   Definition of positive/close margin   Axillary lymph node metastasis   PMRT                                                Local recurrence rate
  ------------------------------------------------------------ ------ -------------------------- --------------------------------------- ------------------------------------- -------------------------------- --------------------------------------------------- -----------------------
  Mentzer et al.[20](#ajco13276-bib-0020){ref-type="ref"}      1986   1974‐1982                  100                                     ≤30 mm                                Included                         Both[a](#ajco13276-tbl2-note-0002){ref-type="fn"}   8.0%
  Ahlborn et al.[21](#ajco13276-bib-0021){ref-type="ref"}      1988   1975‐1980                  88                                      ≤4 mm                                 Excluded                         No                                                  5.7%
  Katz et al.[22](#ajco13276-bib-0022){ref-type="ref"}         2001   1975‐1994                  29                                      \<5 mm                                Included                         No                                                  45%
  Freedman et al.[17](#ajco13276-bib-0017){ref-type="ref"}     1998   1984‐1993                  34                                      ≤6 mm                                 Included                         No                                                  14.7%
  Feigenberg et al.[18](#ajco13276-bib-0018){ref-type="ref"}   2003   1978‐1998                  49                                      ≤2 mm                                 Included                         Yes                                                 6.1%

Abbreviation: PMRT, postmastectomy radiation therapy.

This study included patients with or without PMRT.
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